Filing Flows › Standard Biotools (LAB) › Stock forecast & fair value
Standard Biotools (LAB) stock forecast and price target
Standard Biotools (LAB) trades at $0.64. One analyst's price target is $1.35 (+112%).
Standard Biotools' latest quarter
Standard Biotools, Q3 2026: revenue $19.4M (-0.9% year over year), operating margin -102.0%, net earnings $13.5M, operating cash flow −$6.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for LAB stock?
One analyst's 12-month target is $1.35, +112% from $0.64. The average rating is none.
Does Standard Biotools usually beat earnings estimates?
It beat the consensus EPS estimate in 50% of the quarters on record.
Is LAB stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.